Literature DB >> 15822130

Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma.

Dae Yong Kim1, Won Park, Do Hoon Lim, Joon Hyoek Lee, Byung Chul Yoo, Seung Woon Paik, Kwang Cheol Kho, Tae Hyun Kim, Yong Chan Ahn, Seung Jae Huh.   

Abstract

BACKGROUND: Portal vein thrombosis (PVT) is a common complication in patients with advanced-stage hepatocellular carcinoma (HCC). The authors evaluated the impact of radiotherapy (RT) for PVT of HCC and analyzed the dose-response relation between RT and PVT.
METHODS: Between March 1995 and December 2003, 59 patients diagnosed as HCC with PVT were included. The inclusion criteria were unresectable tumor with thrombosis in the main or first branch of the portal vein, liver function of Child-Pugh Class A or B, and an Eastern Cooperative Oncology Group performance status score of 0-2. The median age of the patients was 57 years (range, 36-78 years). A daily dose ranging from 2 to 3 gray (Gy) was administered using 6 or 10-megavolt (MV) X-rays, at 5 fractions a week, to deliver a total dose range of 30-54 Gy, which was a biologic effective dose of 39-70.2 Gy(10) with an alpha/beta ratio of 10.
RESULTS: Follow-up computed tomography scans showed a complete response (CR) in 4 of 59 patients (6.8%), a partial response (PR) in 23 patients (39.0%), no response (NR) in 28 patients (47.5%), and progressive disease (PD) in 4 patients (6.8%). The mean RT doses in the responders (CR and PR) and nonresponders (NR and PD) were 59.6 +/- 5.6 Gy(10) and 54.9 +/- 8.5 Gy(10), respectively (P = 0.036). The response rates in patients receiving < 58 Gy(10) and > or = 58 Gy(10) were 20% and 54.6%, respectively (P = 0.034). The median survival duration and the 1-year and 2-year survival rates in the responders were 10.7 months, 40.7%, and 20.7%, respectively, and were 5.3 months, 25.0%, and 4.7%, respectively, in the nonresponders (P = 0.050).
CONCLUSIONS: RT induced a 45.8% objective response rate for PVT in patients with HCC. A dose-response relation was found to exist between the RT dose and PVT response. These results suggested that RT may be a treatment option for PVT in patients with HCC and that an RT dose > or = 58 Gy(10) should be recommended.

Entities:  

Mesh:

Year:  2005        PMID: 15822130     DOI: 10.1002/cncr.21043

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  81 in total

1.  Factors linked to longterm survival of patients with hepatocellular carcinoma accompanied by tumour thrombus in the major portal vein after surgical resection.

Authors:  Rumi Matono; Shohei Yoshiya; Takashi Motomura; Takeo Toshima; Hiroto Kayashima; Toshiro Masuda; Tomoharu Yoshizumi; Akinobu Taketomi; Ken Shirabe; Yoshihiko Maehara
Journal:  HPB (Oxford)       Date:  2012-02-03       Impact factor: 3.647

2.  Unresectable Hepatocellular Carcinoma Due to Portal Venous Thrombosis: Focal Stereotactic Body Radiation Therapy Can Promote Resectability.

Authors:  Andrew Y Lee; Tianming Wu; Michael W Vannier; Giuliano Testa; Stanley L Liauw
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 3.  Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus.

Authors:  Masami Minagawa; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

4.  Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma.

Authors:  Young Je Park; Do Hoon Lim; Seung Woon Paik; Kwang Cheol Koh; Joon Hyoek Lee; Moon Seok Choi; Byung Chul Yoo; Hee Rim Nam; Dong Ryul Oh; Won Park; Yong Chan Ahn; Seung Jae Huh
Journal:  J Gastroenterol       Date:  2006-12-08       Impact factor: 7.527

5.  Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Sung Uk Lee; Joong-Won Park; Tae Hyun Kim; Yeon-Joo Kim; Sang Myung Woo; Young-Hwan Koh; Woo Jin Lee; Sang-Jae Park; Dae Yong Kim; Chang-Min Kim
Journal:  Strahlenther Onkol       Date:  2014-03-04       Impact factor: 3.621

6.  Successful multimodality treatment for advanced hepatocellular carcinoma with tumor thrombosis of the main portal trunk: a case study.

Authors:  Yumi Kosaka; Tomokazu Kawaoka; Yutaro Ogawa; Kei Amioka; Kensuke Naruto; Yuki Yoshikawa; Yuwa Ando; Yosuke Suehiro; Kenji Yamaoka; Yasutoshi Fujii; Shinsuke Uchikawa; Atsushi Ono; Masami Yamauchi; Michio Imamura; Keigo Chosa; Kazuo Awai; Yasushi Nagata; Kazuaki Chayama; Hiroshi Aikata
Journal:  Clin J Gastroenterol       Date:  2021-07-21

7.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

8.  Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.

Authors:  Sang Min Yoon; Baek-Yeol Ryoo; So Jung Lee; Jong Hoon Kim; Ji Hoon Shin; Ji Hyun An; Han Chu Lee; Young-Suk Lim
Journal:  JAMA Oncol       Date:  2018-05-01       Impact factor: 31.777

9.  Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study.

Authors:  Qing-he Tang; Ai-jun Li; Guang-ming Yang; Eric C H Lai; Wei-ping Zhou; Zhi-hao Jiang; Wan Yee Lau; Meng-chao Wu
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

Review 10.  Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Dong Soo Lee; Jinsil Seong
Journal:  Liver Cancer       Date:  2014-03       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.